These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

623 related items for PubMed ID: 14576841

  • 1. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling.
    Clarke R, Liu MC, Bouker KB, Gu Z, Lee RY, Zhu Y, Skaar TC, Gomez B, O'Brien K, Wang Y, Hilakivi-Clarke LA.
    Oncogene; 2003 Oct 20; 22(47):7316-39. PubMed ID: 14576841
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
    Kurokawa H, Arteaga CL.
    Clin Cancer Res; 2001 Dec 20; 7(12 Suppl):4436s-4442s; discussion 4411s-4412s. PubMed ID: 11916237
    [Abstract] [Full Text] [Related]

  • 3. [Hormone resistance and its modulation in breast cancer].
    Kahán Z, Thurzó L.
    Orv Hetil; 2005 Apr 17; 146(16):731-7. PubMed ID: 15889669
    [Abstract] [Full Text] [Related]

  • 4. Gene expression changes during the development of estrogen-independent and antiestrogen-resistant growth in breast cancer cell culture models.
    Pennanen PT, Sarvilinna NS, Ylikomi TJ.
    Anticancer Drugs; 2009 Jan 17; 20(1):51-8. PubMed ID: 19343000
    [Abstract] [Full Text] [Related]

  • 5. Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites.
    Liu X, Pisha E, Tonetti DA, Yao D, Li Y, Yao J, Burdette JE, Bolton JL.
    Chem Res Toxicol; 2003 Jul 17; 16(7):832-7. PubMed ID: 12870885
    [Abstract] [Full Text] [Related]

  • 6. Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors.
    Johnston SR, Lu B, Dowsett M, Liang X, Kaufmann M, Scott GK, Osborne CK, Benz CC.
    Cancer Res; 1997 Sep 01; 57(17):3723-7. PubMed ID: 9288779
    [Abstract] [Full Text] [Related]

  • 7. Artemin is estrogen regulated and mediates antiestrogen resistance in mammary carcinoma.
    Kang J, Qian PX, Pandey V, Perry JK, Miller LD, Liu ET, Zhu T, Liu DX, Lobie PE.
    Oncogene; 2010 Jun 03; 29(22):3228-40. PubMed ID: 20305694
    [Abstract] [Full Text] [Related]

  • 8. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA, Robertson KE, Ravel P, Bray SE, Bajard A, Purdie CA, Nguyen C, Hadad SM, Bieche I, Chabaud S, Bachelot T, Thompson AM, Cohen PA.
    Breast Cancer Res; 2008 Jun 03; 10(5):R88. PubMed ID: 18928543
    [Abstract] [Full Text] [Related]

  • 9. Clusterin: a potential target for improving response to antiestrogens.
    Toffanin S, Daidone MG, Miodini P, De Cecco L, Gandellini P, Cappelletti V.
    Int J Oncol; 2008 Oct 03; 33(4):791-8. PubMed ID: 18813793
    [Abstract] [Full Text] [Related]

  • 10. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant.
    Fan M, Yan PS, Hartman-Frey C, Chen L, Paik H, Oyer SL, Salisbury JD, Cheng AS, Li L, Abbosh PH, Huang TH, Nephew KP.
    Cancer Res; 2006 Dec 15; 66(24):11954-66. PubMed ID: 17178894
    [Abstract] [Full Text] [Related]

  • 11. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.
    Chu I, Blackwell K, Chen S, Slingerland J.
    Cancer Res; 2005 Jan 01; 65(1):18-25. PubMed ID: 15665275
    [Abstract] [Full Text] [Related]

  • 12. Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer.
    Lee AV, Cui X, Oesterreich S.
    Clin Cancer Res; 2001 Dec 01; 7(12 Suppl):4429s-4435s; discussion 4411s-4412s. PubMed ID: 11916236
    [Abstract] [Full Text] [Related]

  • 13. Role of estrogen receptor alpha transcriptional coregulators in tamoxifen resistance in breast cancer.
    Girault I, Bièche I, Lidereau R.
    Maturitas; 2006 Jul 20; 54(4):342-51. PubMed ID: 16822624
    [Abstract] [Full Text] [Related]

  • 14. Cyclin D1 expression is dependent on estrogen receptor function in tamoxifen-resistant breast cancer cells.
    Kilker RL, Hartl MW, Rutherford TM, Planas-Silva MD.
    J Steroid Biochem Mol Biol; 2004 Sep 20; 92(1-2):63-71. PubMed ID: 15544931
    [Abstract] [Full Text] [Related]

  • 15. A 2009 update on the treatment of patients with hormone receptor-positive breast cancer.
    Cleator SJ, Ahamed E, Coombes RC, Palmieri C.
    Clin Breast Cancer; 2009 Jun 20; 9 Suppl 1():S6-S17. PubMed ID: 19561006
    [Abstract] [Full Text] [Related]

  • 16. Ligand-induced regulation of ERalpha and ERbeta is indicative of human breast cancer cell proliferation.
    Power KA, Thompson LU.
    Breast Cancer Res Treat; 2003 Oct 20; 81(3):209-21. PubMed ID: 14620916
    [Abstract] [Full Text] [Related]

  • 17. Characterization of a human breast cancer cell line, MCF-7/RU58R-1, resistant to the pure antiestrogen RU 58,668.
    Fog CK, Christensen IJ, Lykkesfeldt AE.
    Breast Cancer Res Treat; 2005 May 20; 91(2):133-44. PubMed ID: 15868441
    [Abstract] [Full Text] [Related]

  • 18. Positive feedback activation of estrogen receptors by the CXCL12-CXCR4 pathway.
    Sauvé K, Lepage J, Sanchez M, Heveker N, Tremblay A.
    Cancer Res; 2009 Jul 15; 69(14):5793-800. PubMed ID: 19584281
    [Abstract] [Full Text] [Related]

  • 19. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance.
    Lewis JS, Jordan VC.
    Mutat Res; 2005 Dec 11; 591(1-2):247-63. PubMed ID: 16083919
    [Abstract] [Full Text] [Related]

  • 20. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
    Hoffmann J, Sommer A.
    J Steroid Biochem Mol Biol; 2005 Feb 11; 93(2-5):191-200. PubMed ID: 15860262
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.